<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1369293</PMID><DateCompleted><Year>1991</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-1369</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>7</Issue><PubDate><Year>1990</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Agricultural and biological chemistry</Title><ISOAbbreviation>Agric Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Isolation and characterization of opioid antagonist peptides derived from human lactoferrin.</ArticleTitle><Pagination><StartPage>1803</StartPage><EndPage>1810</EndPage><MedlinePgn>1803-10</MedlinePgn></Pagination><Abstract><AbstractText>Peptides with affinity for opioid receptors were found in an artificially methyl-esterified peptic digest of human lactoferrin. Three active peptides were purified by two steps of reverse-phase high-performance liquid chromatography. Their structures were Tyr-Leu-Gly-Ser-Gly-Tyr-OCH3, Arg-Tyr-Tyr-Gly-Tyr-OCH2, and Lys-Tyr-Leu-Gly-Pro-Gln-Tyr-OCH3, which respectively correspond to the methyl esters of residues 318-323, 536-540, and 673-679 of human lactoferrin. The IC50 values of these peptides were 15, 10 and 23 microM, respectively, in a radioreceptor assay in the presence of 1 nM [3H]naloxone. In the myenteric plexus preparation of the longitudinal muscle of guinea pig ileum, the individual peptides had no opioid agonist activities, but they antagonized [Met5]enkephalin and morphiceptin when they were at a concentration of 10(-6)-10(-5) M, suggesting that these were the opioid antagonist peptides. These three opioid antagonist peptides were named lactoferroxin A, B and C, after casoxin, the opioid antagonist peptide derived from bovine kappa-casein. Concerning the antagonist activities of lactoferroxins for opioid receptor sub-types, lactoferroxin A showed preference for mu-receptors, while lactoferroxin B and C had somewhat higher degrees of preference for kappa-receptors than for mu-receptors. A study of the structure-activity relationship of the three lactoferroxins and their synthetic analogues showed that these opioid antagonist peptides derived from food protein could be expressed by the general formula XA-Tyr-XB-Tyr-OCH3. An amino acid in position XA may affect the specificity of the antagonist peptide for opioid receptor sub-types.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Food Science and Technology, Faculty of Agriculture, Kyoto University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iio</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Chiba</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yoshikawa</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Agric Biol Chem</MedlineTA><NlmUniqueID>0370452</NlmUniqueID><ISSNLinking>0002-1369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011957">Receptors, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>117667-25-1</RegistryNumber><NameOfSubstance UI="C067917">lactoferroxin-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>117667-26-2</RegistryNumber><NameOfSubstance UI="C067918">lactoferroxin-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>117667-27-3</RegistryNumber><NameOfSubstance UI="C067919">lactoferroxin-C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D007781">Lactoferrin</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007781" MajorTopicYN="N">Lactoferrin</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009292" MajorTopicYN="N">Narcotic Antagonists</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011957" MajorTopicYN="N">Receptors, Opioid</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1369293</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>